Research in Brief: Hemodiafiltration and hospitalization burden in ESKD

People on dialysis continue to face elevated rates of hospitalization and mortality. Recent clinical evidence, including results from the CONVINCE trial and pooled analyses, has shown that hemodiafiltration (HDF) may offer advantages over conventional hemodialysis, particularly in reducing mortality risk.

To further explore HDF’s broader clinical impact, a large real-world study compared HDF with high-flux hemodialysis across 71,669 patients treated in 659 Fresenius Medical Care centers in 23 countries in Europe, the Middle East, and Africa between 2019 and 2022.

Yan Zhang, PhD, Senior Expert in Real-World Data Analysis at the Renal Research Institute, discusses this study in this latest Research in Brief. The analysis found that HDF may help reduce hospitalization burden for individuals with end stage kidney disease (ESKD), especially hospitalizations related to cardiovascular complications and fluid management issues.

These findings add to the growing evidence base indicating that HDF provides a wide range of clinical benefits — improving survival, supporting better overall health outcomes, and enhancing the quality of care for people on dialysis.

Read more about this study here.